First-in-humans test provides promising results for a broadly neutralizing antibody HIV vaccine

A Phase 1 clinical trial provides promising results for a broadly neutralizing antibody (bnAb) HIV vaccine, according to a new study.

Related Keywords

David Leggat ,Penny Moore ,Emily Henderson ,Lab Diagnostics Automation ,Lab Diagnostics Automation Industry ,Automation Industry Focus ,Antibody ,Germline ,Shiv ,Vaccine ,Kids ,Clinical Trial ,Hiv Aids ,Pandemic ,